William Blair: 'view BridgeBio as becoming a core smidcap biotech holding'
Tweet Send to a Friend
William Blair analyst John Boyle reiterated an Outperform rating on BridgeBio Pharma (NASDAQ: BBIO).The analyst comments "For BridgeBio, while the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




